Biomarkers and Surrogate Endpoints: How and When might They Impact Drug Development?
Biomarkers and Surrogate Endpoints: How and When might They Impact Drug Development?
As the pharmaceutical industry starts developing novel molecules developed based on molecular biology principles and a better understanding of the human genome, it becomes increasingly important to develop early indicators of activity and/or toxicity. Biomarkers are measurements based on molecular pharmacology and/or pathophysiology of the disease being evaluated that may …